DelveInsight’s “PD-1 Resistant Head and Neck Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the PD-1 Resistant Head and Neck Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging PD-1 Resistant Head and Neck Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current PD-1 Resistant Head and Neck Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
PD-1 Resistant Head and Neck Cancer: An Overview
Head and Neck Cancers usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck (for example, inside the mouth, the nose, and the throat). These squamous cell cancers are often referred to as squamous cell carcinoma or Head and Neck Cancer. The symptoms of Head and Neck Cancers may include a lump or a sore that does not heal, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. Symptoms may vary depending on the site of the cancer.
Cancer cells have the ability to spread to other parts of the body. Cancer cells in the head or neck can sometimes travel to the lungs and grow there. When cancer cells do this, it’s called metastasis. Patients who demonstrate growth of cancer outside of the original head and neck site or lymph nodes of the head and neck have developed distant metastases, and are considered to have incurable disease.
Compared with the traditional treatments, the up-and-coming anti-PD-1/PD-L1 agents present better efficacy and lower toxicity for patients with advanced HNSCC.
Alcohol and tobacco use are the two most important risk factors for Head and Neck Cancers, especially cancers of the oral cavity, oropharynx, hypopharynx, and larynx. At least 75% of Head and Neck Cancers are caused by tobacco and alcohol use. Infection with cancer-causing types of human papillomavirus (HPV), especially HPV type 16, is a risk factor for some types of Metastatic Head and Neck Cancers, particularly oropharyngeal cancers that involve the tonsils or the base of the tongue.
PD-1 Resistant Head and Neck Cancer Market Key Facts
As per the World Health Organization (WHO) (2014), Head and Neck Cancer encompasses many site-specific cancers, including oral cavity and oropharyngeal cancers. Studies have estimated the global incidence of all Metastatic Head and Neck Cancers to be between 400,000 and 600,000 new cases per year and the mortality rate is between 223,000 and 300,000 deaths per year.
According to Shayan et al., (2016), anti-PD-1 single agent response rates are only <20% in head and neck squamous cell carcinoma (HNSCC) patients, it is important to understand how multiple inhibitory checkpoint receptors maintain suppressed cellular Immunity.
According to the study conducted by Oliva et al., (2019), up to 60% of patients across different tumor types, including HNSCC, display primary resistance to anti-PD-1/PD-L1 agents
As per Adamson et al. (2019), a sensitivity analysis of metastatic head and neck cancer by site showed a 22.9% increase in the incidence of oropharyngeal cancer (0.21 per 100,000 person-years in 2004 vs. 0.25 per 100,000 person-years in 2015). Additionally, investigators reported significant rate increases among those aged 50 years and older.
PD-1 Resistant Head and Neck Cancer Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging PD-1 Resistant Head and Neck Cancer pipeline therapies. It also thoroughly assesses the PD-1 Resistant Head and Neck Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed PD-1 Resistant Head and Neck Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
PD-1 Resistant Head and Neck Cancer Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted PD-1 Resistant Head and Neck Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted PD-1 Resistant Head and Neck Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the PD-1 Resistant Head and Neck Cancer Epidemiology, Segmented as –
Incident cases of Head and Neck Cancer (HNC) in the 7MM (2019–2032)
Treatable Cases of PD-1 resistant HNC in the 7MM (2019–2032)
Incident cases of PD-1 resistant HNC in the 7MM (2019–2032)
Treatable cases of Head and Neck Cancer (HNC) in the 7MM (2019–2032)
PD-1 Resistant Head and Neck Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the PD-1 Resistant Head and Neck Cancer market or expected to be launched during the study period. The analysis covers the PD-1 Resistant Head and Neck Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the PD-1 Resistant Head and Neck Cancer drugs based on their sale and market share.
The report also covers the PD-1 Resistant Head and Neck Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key PD-1 Resistant Head and Neck Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the PD-1 Resistant Head and Neck Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/pd-1-resistant-head-and-neck-cancer-hnc-market
PD-1 Resistant Head and Neck Cancer Therapeutics Analysis
For those able to receive treatment for metastatic spread, treatment again consists mainly of systemic therapies: cytotoxic chemotherapy, cytotoxic chemotherapy combined with cetuximab, or immunotherapy. For those who have a significant burden of symptoms but are still able to receive systemic therapy, single agent rather than combination therapy is recommended. For those with a minimal burden of symptoms and a good ability to participate in the daily activities of life, multi-agent systemic therapy is the treatment of choice after clinical trial enrollment and can consist of the agents in the local/regional recurrence. Usually, if the cancer becomes resistant to the current regimen, the patient is switched to new regimens until the patient is unable to tolerate further therapy or the cancer grows beyond the control of any therapy. At that time, palliative care services were essential for symptom control, end-of-life planning, and psychological counseling.
Radiation therapy is the use of high-energy X-rays or other particles to destroy cancer cells. A radiation therapy regimen, or schedule, usually consists of a specific number of treatments given over a set period of time. It can be the main treatment for Metastatic Head and Neck Cancer, or it can be used after surgery to destroy small areas of cancer that cannot be removed surgically.
PD-1 Resistant Head and Neck Cancer Companies Actively Working in the Therapeutics Market Include
Merck
Nanobiotix
And Many Others
Emerging and Marketed PD-1 Resistant Head and Neck Cancer Therapies Covered in the Report Include:
Keytruda (MK-3475): Merck
NBTXR3: Nanobiotix
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. PD-1 Resistant Head and Neck Cancer Competitive Intelligence Analysis
4. PD-1 Resistant Head and Neck Cancer Market Overview at a Glance
5. PD-1 Resistant Head and Neck Cancer Disease Background and Overview
6. PD-1 Resistant Head and Neck Cancer Patient Journey
7. PD-1 Resistant Head and Neck Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. PD-1 Resistant Head and Neck Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. PD-1 Resistant Head and Neck Cancer Unmet Needs
10. Key Endpoints of PD-1 Resistant Head and Neck Cancer Treatment
11. PD-1 Resistant Head and Neck Cancer Marketed Therapies
12. PD-1 Resistant Head and Neck Cancer Emerging Drugs and Latest Therapeutic Advances
13. PD-1 Resistant Head and Neck Cancer Seven Major Market Analysis
14. Attribute Analysis
15. PD-1 Resistant Head and Neck Cancer Market Outlook (In US, EU5, and Japan)
16. PD-1 Resistant Head and Neck Cancer Companies Active in the Market
17. PD-1 Resistant Head and Neck Cancer Access and Reimbursement Overview
18. KOL Views on the PD-1 Resistant Head and Neck Cancer Market
19. PD-1 Resistant Head and Neck Cancer Market Drivers
20. PD-1 Resistant Head and Neck Cancer Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Erythema Market
“Erythema Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Erythema market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Erythema market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailAddress:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/medical-devices
